COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations is a paper indexed in ScholarIQ from OpenAlex.
How many citations does COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations have?
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations has 186 citations in the OpenAlex counts ScholarIQ stores.
When was COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations published?
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations has 2022 year in the ScholarIQ index.
What is the open-access status of COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations?
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations has bronze oa status in the ScholarIQ index.
What is the DOI of COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations?
The DOI for COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations is on the source record.
What is the PMID of COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations?
The PMID for COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations is on the source record.
What is the OpenAlex record for COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations?
The OpenAlex for COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations is on the source record.